- Biotech stock BriaCell Therapeutics (TSX:BCT; NDAQ:BCTX) has released Phase 2 clinical data showing strong patient survival benefit and clinical benefit in advanced metastatic breast cancer patients
- Data includes a median survival rate of 13.5 months compared with 6.7-9.8 months for similar patients in previous studies
- BriaCell Therapeutics is a clinical-stage biotechnology company developing immunotherapies to transform cancer care
- BriaCell Therapeutics stock (TSX:BCT; NDAQ:BCTX) is down by 75.47 per cent over the past five years
Biotech stock BriaCell Therapeutics (TSX:BCT; NDAQ:BCTX) has released Phase 2 clinical data showing strong patient survival benefit and clinical benefit in advanced metastatic breast cancer patients.
The fully enrolled study is treating 46 heavily pretreated (average of five prior treatments) advanced metastatic breast cancer patients with BriaCell’s lead clinical candidate, Bria-IMT, and an immune checkpoint inhibitor combination regimen.
The regimen includes 11 patients on Merck’s KEYTRUDA (pembrolizumab) and 36 patients on Incyte’s ZYNYZ (retifanlimab-dlwr). Twenty-nine patients have received treatment since 2022.
Phase 2 study findings
- Treatment tolerability has led to no dose-limiting toxicities.
- 21 out of 29 patients treated since 2022 remain alive, which suggests tolerability and survival efficacy. That said, data will only be considered mature once all patients finalize the study.
- Median overall survival rate of 13.5 months using the Kaplan-Meier curve method, which measures the probability of patients’ survival in time. The overall survival in advanced breast cancer patients (third line or later) is very limited, with a range of 6.7-9.8 months in publications that evaluated similar patients.
Management believes the findings support additive and/or synergistic effects of immune checkpoint inhibitors with Bria-IMT and their continued study toward a viable treatment for advanced breast cancer.
“The promising survival data of BriaCell’s combination regimen suggests the potential for an industry-shaping leap in advanced metastatic breast cancer treatment,” Carmen Calfa, M.D., associate professor of clinical medicine at the University of Miami and principal clinical investigator of the Phase 2 Bria-IMT study, said in a statement. “The overall safety profile and survival data in advanced metastatic breast cancer is extremely encouraging in this heavily pretreated patient population.”
“We are forging a new path for advanced metastatic breast cancer, a terminal disease with a very limited life expectancy of 6.7 to 9.8 months,” Dr. William V. Williams, BriaCell’s president and CEO, said in a statement. “The impressive survival benefit and tolerability of the Bria-IMT regimen highlights the importance of this treatment option for patients in which all other therapies have failed.”
The news follows BriaCell’s research grant from the National Cancer Institute to advance its off-the-shelf immunotherapies for breast, prostate, lung and skin cancer.
BriaCell Therapeutics is a clinical-stage biotechnology company developing immunotherapies to transform cancer care.
BriaCell Therapeutics (TSX:BCT; NDAQ:BCTX) is up by 4.24 per cent trading at $9.59 per share as of 9:42 am ET. The stock is down by 75.47 per cent over the past five years.
Join the discussion: Find out what everybody’s saying about this stock on the BriaCell Therapeutics Bullboard, and check out the rest of Stockhouse’s stock forums and message boards.
The material provided in this article is for information only and should not be treated as investment advice. For full disclaimer information, please click here.